Green tea compound tested as potential new treatment for scarred lungs
NCT ID NCT05195918
Summary
This study is testing whether a purified compound from green tea, called EGCG, is safe for people with idiopathic pulmonary fibrosis (IPF), a serious disease that causes lung scarring. The 12-week trial involves about 50 patients who are already taking standard IPF medications. Researchers will check for side effects and see if EGCG shows any early signs of affecting the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
-
UCSF Parnassus
San Francisco, California, 94143, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.